A5089873087- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Chemokine receptors and signaling
- Cancer Genomics and Diagnostics
- Protein Degradation and Inhibitors
- Circular RNAs in diseases
- MicroRNA in disease regulation
- Glycosylation and Glycoproteins Research
- Immunotherapy and Immune Responses
- Extracellular vesicles in disease
- Immune cells in cancer
- Cancer-related molecular mechanisms research
- Hematopoietic Stem Cell Transplantation
- Renal Diseases and Glomerulopathies
- Monoclonal and Polyclonal Antibodies Research
- Hematological disorders and diagnostics
- Platelet Disorders and Treatments
- Cancer therapeutics and mechanisms
- Phytochemical compounds biological activities
- Cancer Treatment and Pharmacology
- Acute Myeloid Leukemia Research
- Peptidase Inhibition and Analysis
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Bone and Joint Diseases
University Hospital Brno
2016-2025
Erasmus MC
2023
University Hospital Ostrava
2023
Masaryk University
2016-2021
Chonnam National University Hwasun Hospital
2019
Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating cells (CTCs) until 2021, when this threshold decreased to 5%. We hypothesized that primary PCL not a separate clinical entity, but rather it represents ultra-high-risk multiple myeloma (MM) elevated CTC levels.We assessed levels of CTCs multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM establish cutoff for identifies...
ABSTRACT Multiple myeloma is a plasma cell malignancy characterized by an abnormal increase in monoclonal immunoglobulins. Despite significant advances treatment, some patients progress to more aggressive forms of multiple myeloma, including extramedullary disease or leukemia. Although the exact molecular mechanisms are not known, several studies have confirmed involvement small extracellular vesicle‐enriched microRNAs progression. Therefore, we performed expression profiling these molecules...
Long non-coding RNAs (lncRNAs) are RNA transcripts longer than 200 nucleotides that not translated into proteins. They involved in pathogenesis of many diseases including cancer and have a potential to serve as diagnostic prognostic markers. We aimed investigate lncRNA expression profiles bone marrow plasma cells (BMPCs) newly diagnosed multiple myeloma (MM) patients comparison normal BMPCs healthy donors (HD) three-phase biomarker study.Expression profile 83 was performed by RT2 PCR Array...
Abstract Objectives Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used this purpose; however, approach site‐limited. Liquid biopsy represents a minimally invasive and more comprehensive technique that not site‐limited, but equally challenging. Methods While majority current data comes from short‐term studies, we present long‐term study on...
Summary Plasma cell leukaemia (PCL) is a rare and very aggressive plasma disorder. Preventing dismal outcome of PCL requires early diagnosis with appropriate analytical tools. Therefore, the investigation 33 patients primary secondary was done when quantity circulating cells (PCs) using flow cytometry (FC) morphology assessment evaluated. The phenotypic profile PCs also analysed to determine if there an association clinical outcomes evaluate prognostic value markers. Our results revealed...
Long non-coding RNAs (lncRNAs) are functional longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay multiple myeloma (MM) and plasma cell leukemia (PCL) is virtually absent. Herein, we aimed identify involved MM PCL progression. We investigated representative datasets patients using next-generation sequencing. In total, 13 deregulated (p < 0.00025) were identified; four...
Aldehyde dehydrogenase (ALDH) is highly active in physiological stem cells as well tumor-initiating of some malignancies including multiple myeloma (MM). Finding higher activity ALDH cell subsets monoclonal gammopathies (MG) could identify potential source myeloma-initiating (MICs).Bone marrow 12 MM, 9 gammopathy undetermined significance (MGUS), and 10 healthy donors (HD) were analyzed by flow cytometry. B-cells plasma (PC) was using Aldefluor.Similar changes found during B-cell development...
ABSTRACT Minimal residual disease (MRD) is one of the most important prognostic factors in multiple myeloma (MM) and a valid surrogate for progression‐free survival (PFS) overall (OS). Recently, MRD negativity was approved as an early clinical endpoint accelerated drug approval MM. Nevertheless, there limited evidence utility real‐world setting. In this retrospective multicenter study, we report outcomes 331 newly diagnosed MM patients with evaluation at Day+100 after autologous stem cell...
Despite the high efficacy of current induction regimens, most multiple myeloma (MM) patients relapse over time.The link between changes in immune system and prognosis disease is still not entirely clear.Therefore, we analyzed whether pattern bone marrow (BM) lymphocytes during routine BM examination after autologous stem cell transplant (ASCT) related to or MRD negative complete remission.From 2009 2018, 98 MM underwent testing first ASCT.Using multi-parametric flow cytometry, twelve...
Adaptive response to hypoxia is regulated by several mechanisms and transcription factors, including hypoxia-inducible factors (HIFs). Activation of HIF-1α associated with increased expression P-glycoprotein multidrug resistance in cancer cells. In this retrospective study, we analyzed candidate single-nucleotide polymorphisms (SNPs) HIF-1β risk monoclonal gammopathy undetermined significance (MGUS) or multiple myeloma (MM).Genotypes SNPs were determined an independent cohort gammopathies...
Plasma cell leukemia (PCL) is a rare dis-ease and possibly the most aggressive form of monoclonal gammopathy. It classified into two forms -  primary PCL that occurs without previously identifiable multiple myeloma stage, secondary develops from dia-gnosed myeloma. These have different cytogenetic molecular profiles, but both an clinical course. Combinations therapeutic approaches includ-ing autologous stem transplantation currently proteasome inhibitors immunomodulatory drugs are used...